Urry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald

Urry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA: NRAS mutation status is definitely an independent prognostic element in metastatic melanoma. Cancer 2012, 118:4014023. 5. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012, 18:1503510. 6. Yeh I, von Deimling A, Bastian BC: Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst 2013, 105:91719. 7. Birkeland E, Busch C, Berge EO, Geisler J, Jonsson G, Lillehaug JR, Knappskog S, Lonning PE: Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clin Exp Metastasis 2013, 30(7):8676. 8. Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G: Disease progression and patient survival Are substantially influenced by BRAF protein expression in principal melanoma. Br J Dermatol 2013, 169(two):320. 9. Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM: Advances in therapy for melanoma brain metastases. Clin Dermatol 2013, 31:26481. ten. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP: Mutant V599EB-Raf regulates development and vascular development of malignant melanoma tumors. Cancer Res 2005, 65:2412421. 11. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Woude GF, Webb CP: Suppression of Ras-mediated tumorigenicity and metastasis by way of inhibition of your Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001, 98:107220727. 12. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma.Ripretinib N Engl J Med 2010, 363:80919.Paricalcitol 13.PMID:24578169 Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P: Vemurafenib: the first drug authorized for BRAF-mutant cancer. Nat Rev Drug Discov 2012, 11:87386. 14. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Mart -Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB: Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase three randomised controlled trial. Lancet 2012, 380:35865. 15. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:10714. 16. Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:51731.YUVON, YUROB, YUKSI, YUMAC, YUDOSO and YUKIM cells had been plated at 1,000 per nicely in six-well plates to supply an optimal counting density. Cells have been treated with escalating concentrations of MEK162 (0.1 nM 1000 nM) and cultured for 1 to two weeks until well-defined colonies had formed (30 cells/colony), replacing culture medium every single three days. Cells have been fixed and stained with 0.25 w/v crystal violet in 80 methanol answer. Digital images of six-well plates have been captured, and colonies had been counted employing ProtoCOL s.